1. Spitznas M, Huke J. Number, shape, and topography of leakagepoints in acute type I central serous retinopathy. Graefes Arch ClinExp Ophthalmol. 1987;225(6):437-440. doi:10.1007/BF02334172
2. Yamada K, Hayasaka S, Setogawa T. Fluorescein-angiographicpatterns in patients with central serous chorioretinopathyat the initial visit. Ophthalmologica. 1992;205(2):69-76.doi:10.1159/000310315
3. Bujarborua D, Nagpal PN, Deka M. Smokestack leak in centralserous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol.2010;248(3):339-351. doi:10.1007/s00417-009-1212-5
4. Yang L, Jonas JB, Wei W. Optical coherence tomography-assistedenhanced depth imaging of central serous chorioretinopathy. InvestOphthalmol Vis Sci. 2013;54(7):4659-4665. Published 2013 Jul 12.doi:10.1167/iovs.12-10991
5. Ellabban AA, Tsujikawa A, Ooto S, et al. Focal choroidal excavationin eyes with central serous chorioretinopathy. Am J Ophthalmol.2013;156(4):673-683. doi:10.1016/j.ajo.2013.05.010
6. Imamura Y, Fujiwara T, Margolis R, Spaide RF. Enhanceddepth imaging optical coherence tomography of the choroid incentral serous chorioretinopathy. Retina. 2009;29(10):1469-1473.doi:10.1097/IAE.0b013e3181be0a83
7. Lehmann M, Bousquet E, Beydoun T, Behar-Cohen F.PACHYCHOROID: an inherited condition?. Retina. 2015;35(1):10-16. doi:10.1097/IAE.0000000000000287
8. Lehmann M, Wolff B, Vasseur V, et al. Retinal and choroidal changesobserved with ‘En face’ enhanced-depth imaging OCT in centralserous chorioretinopathy. Br J Ophthalmol. 2013;97(9):1181-1186.doi:10.1136/bjophthalmol-2012-302974
9. Piccolino FC, De La Longrais RR, Manea M, Cicinelli S. Posteriorcystoid retinal degeneration in central serous chorioretinopathy.Retina. 2008;28(7):1008-1012. doi:10.1097/IAE.0b013e31816b4b86
10. Kim HC, Cho WB, Chung H. Morphologic changes in acute centralserous chorioretinopathy using spectral domain optical coherencetomography. Korean J Ophthalmol. 2012;26(5):347-354. doi:10.3341/kjo.2012.26.5.347
11. Matsumoto H, Kishi S, Otani T, Sato T. Elongation of photoreceptorouter segment in central serous chorioretinopathy. Am J Ophthalmol.2008;145(1):162-168. doi:10.1016/j.ajo.2007.08.024
12. Fujimoto H, Gomi F, Wakabayashi T, Sawa M, Tsujikawa M, TanoY. Morphologic changes in acute central serous chorioretinopathyevaluated by fourier-domain optical coherence tomography.Ophthalmology. 2008;115(9):1494-1500.e15002. doi:10.1016/j.ophtha.2008.01.021
13. Ahlers C, Geitzenauer W, Stock G, Golbaz I, Schmidt-Erfurth U,Prünte C. Alterations of intraretinal layers in acute central serouschorioretinopathy. Acta Ophthalmol. 2009;87(5):511-516. doi:10.1111/j.1755-3768.2008.01468.x
14. Matsumoto H, Sato T, Kishi S. Outer nuclear layer thickness atthe fovea determines visual outcomes in resolved central serouschorioretinopathy. Am J Ophthalmol. 2009;148(1):105-10.e1.doi:10.1016/j.ajo.2009.01.018
15. Iida T, Yannuzzi LA, Spaide RF, Borodoker N, Carvalho CA,Negrao S. Cystoid macular degeneration in chronic central serouschorioretinopathy. Retina. 2003;23(1):1-138. doi:10.1097/00006982-200302000-00001
16. Landa G, Barnett JA, Garcia PM, Tai KW, Rosen RB. Quantitative andqualitative spectral domain optical coherence tomography analysis ofsubretinal deposits in patients with acute central serous retinopathy.Ophthalmologica. 2013;230(2):62-68. doi:10.1159/000350231
17. Maruko I, Iida T, Ojima A, Sekiryu T. Subretinal dot-like precipitatesand yellow material in central serous chorioretinopathy. Retina.2011;31(4):759-765. doi:10.1097/IAE.0b013e3181fbce8e
18. von Rückmann A, Fitzke FW, Fan J, Halfyard A, Bird AC. Abnormalitiesof fundus autofluorescence in central serous retinopathy. Am JOphthalmol. 2002;133(6):780-786. doi:10.1016/s0002-9394(02)01428-9
19. Prünte C, Flammer J. Choroidal capillary and venous congestion incentral serous chorioretinopathy. Am J Ophthalmol. 1996;121(1):26-34.doi:10.1016/s0002-9394(14)70531-8
20. Iida T, Kishi S, Hagimura N, Shimizu K. Persistent and bilateralchoroidal vascular abnormalities in central serous chorioretinopathy.Retina. 1999;19(6):508-512. doi:10.1097/00006982-199911000-00005
21. Kitaya N, Nagaoka T, Hikichi T, et al. Features of abnormal choroidalcirculation in central serous chorioretinopathy. Br J Ophthalmol.2003;87(6):709-712. doi:10.1136/bjo.87.6.709
22. Sharma T, Shah N, Rao M, et al. Visual outcome after discontinuationof corticosteroids in atypical severe central serous chorioretinopathy.Ophthalmology. 2004;111(9):1708-1714. doi:10.1016/j.ophtha.2004.03.025
23. Yannuzzi LA. Central serous chorioretinopathy: a personal perspective.Am J Ophthalmol. 2010;149(3):361-363. doi:10.1016/j.ajo.2009.11.017
24. Nicholson B, Noble J, Forooghian F, Meyerle C. Central serouschorioretinopathy: update on pathophysiology and treatment. SurvOphthalmol. 2013;58(2):103-126. doi:10.1016/j.survophthal.2012.07.004
25. Lim JW, Kang SW, Kim YT, Chung SE, Lee SW. Comparative studyof patients with central serous chorioretinopathy undergoing focallaser photocoagulation or photodynamic therapy. Br J Ophthalmol.2011;95(4):514-517. doi:10.1136/bjo.2010.182121
26. Robertson DM, Ilstrup D. Direct, indirect, and sham laserphotocoagulation in the management of central serouschorioretinopathy. Am J Ophthalmol. 1983;95(4):457-466.doi:10.1016/0002-9394(83)90265-9
27. Maruko I, Iida T, Sugano Y, Ojima A, Ogasawara M, Spaide RF.Subfoveal choroidal thickness after treatment of central serouschorioretinopathy. Ophthalmology. 2010;117(9):1792-1799. doi:10.1016/j.ophtha.2010.01.023
28. Peyman GA, Bok D. Peroxidase diffusion in the normal and laser-coagulated primate retina. Invest Ophthalmol. 1972;11(1):35-45.
29. Ficker L, Vafidis G, While A, Leaver P. Long-term follow-up of aprospective trial of argon laser photocoagulation in the treatmentof central serous retinopathy. Br J Ophthalmol. 1988;72(11):829-834.doi:10.1136/bjo.72.11.829
30. Samy CN, Gragoudas ES. Laser photocoagulation treatment of centralserous chorioretinopathy. Int Ophthalmol Clin. 1994;34(3):109-119.doi:10.1097/00004397-199403430-00012
31. Robertson DM, Ilstrup D. Direct, indirect, and sham laserphotocoagulation in the management of central serouschorioretinopathy. Am J Ophthalmol. 1983;95(4):457-466.doi:10.1016/0002-9394(83)90265-9
32. Tarantola RM, Law JC, Recchia FM, Sternberg P Jr, Agarwal A.Photodynamic therapy as treatment of chronic idiopathic centralserous chorioretinopathy. Lasers Surg Med. 2008;40(10):671-675.doi:10.1002/lsm.20720
33. Chan WM, Lai TY, Lai RY, Liu DT, Lam DS. Half-dose verteporfinphotodynamic therapy for acute central serous chorioretinopathy:one-year results of a randomized controlled trial. Ophthalmology.2008;115(10):1756-1765. doi:10.1016/j.ophtha.2008.04.014
34. Dang Y, Sun X, Xu Y, et al. Subfoveal choroidal thickness afterphotodynamic therapy in patients with acute idiopathic central serouschorioretinopathy. Ther Clin Risk Manag. 2014;10:37-43. doi:10.2147/TCRM.S54213
35. Reibaldi M, Cardascia N, Longo A, et al. Standard-fluence versuslow-fluence photodynamic therapy in chronic central serouschorioretinopathy: a nonrandomized clinical trial. Am J Ophthalmol.2010;149(2):307-315.e2. doi:10.1016/j.ajo.2009.08.026
36. Uetani R, Ito Y, Oiwa K, Ishikawa K, Terasaki H. Half-dose vsone-third-dose photodynamic therapy for chronic central serouschorioretinopathy. Eye (Lond). 2012;26(5):640-649. doi:10.1038/eye.2012.66
37. Ober MD, Yannuzzi LA, Do DV, et al. Photodynamic therapy forfocal retinal pigment epithelial leaks secondary to central serouschorioretinopathy. Ophthalmology. 2005;112(12):2088-2094.doi:10.1016/j.ophtha.2005.06.026
38. Yannuzzi LA, Slakter JS, Gross NE, et al. Indocyanine greenangiography-guided photodynamic therapy for treatment of chroniccentral serous chorioretinopathy: a pilot study. Retina. 2003;23(3):288-298. doi:10.1097/00006982-200306000-00002
39. Inoue R, Sawa M, Tsujikawa M, Gomi F. Association between theefficacy of photodynamic therapy and indocyanine green angiographyfindings for central serous chorioretinopathy. Am J Ophthalmol.2010;149(3):441-6.e62. doi:10.1016/j.ajo.2009.10.011
40. Lim JW, Kang SW, Kim YT, Chung SE, Lee SW. Comparative studyof patients with central serous chorioretinopathy undergoing focallaser photocoagulation or photodynamic therapy. Br J Ophthalmol.2011;95(4):514-517. doi:10.1136/bjo.2010.182121
41. Behnia M, Khabazkhoob M, Aliakbari S, Abadi AE, Hashemi H,Pourvahidi P. Improvement in visual acuity and contrast sensitivityin patients with central serous chorioretinopathy after macularsubthreshold laser therapy. Retina. 2013;33(2):324-328. doi:10.1097/IAE.0b013e3182670fa3
42. Brancato R, Pratesi R, Leoni G, Trabucchi G, Vanni U. Histopathologyof diode and argon laser lesions in rabbit retina. A comparative study.Invest Ophthalmol Vis Sci. 1989;30(7):1504-1510.
43. Lanzetta P, Furlan F, Morgante L, Veritti D, Bandello F. Nonvisiblesubthreshold micropulse diode laser (810 nm) treatment ofcentral serous chorioretinopathy. A pilot study. Eur J Ophthalmol.2008;18(6):934-940. doi:10.1177/112067210801800613
44. Gupta B, Elagouz M, McHugh D, Chong V, Sivaprasad S. Micropulsediode laser photocoagulation for central serous chorio-retinopathy.Clin Exp Ophthalmol. 2009;37(8):801-805. doi:10.1111/j.1442-9071.2009.02157.x
45. Çıtırık M. Nondamaging retinal laser therapy in recurrentdiabetic macular edema after antiVEGF injections. Turk J Med Sci.2021;51(5):2616-2620. doi:10.3906/sag-2007-304
46. Ilhan C, Citirik M, Özdemir M. Non-damaging retinal laser therapy inchronic central serous chorioretinopathy. Int Ophthalmol. 2023;10.1007/s10792-023-02691-5. doi:10.1007/s10792-023-02691-5
47. Elsner H, Pörksen E, Klatt C, et al. Selective retina therapy inpatients with central serous chorioretinopathy. Graefes Arch Clin ExpOphthalmol. 2006;244(12):1638-1645. doi:10.1007/s00417-006-0368-5
48. Klatt C, Elsner H, Pörksen E, et al. Selektive Retina-Therapiebei Retinopathia centralis serosa mit Pigmentepithelabhebung.Ophthalmologe. 2006;103(10):850-855. doi:10.1007/s00347-006-1415-7
49. Chung YR, Seo EJ, Lew HM, Lee KH. Lack of positive effect ofintravitreal bevacizumab in central serous chorioretinopathy: meta-analysis and review. Eye (Lond). 2013;27(12):1339-1346. doi:10.1038/eye.2013.236
50. Lim JW, Kim MU, Shin MC. Aqueous humor and plasma levels ofvascular endothelial growth factor and interleukin-8 in patientswith central serous chorioretinopathy. Retina. 2010;30(9):1465-1471.doi:10.1097/IAE.0b013e3181d8e7fe
51. Lim JW, Kim MU. The efficacy of intravitreal bevacizumab foridiopathic central serous chorioretinopathy. Graefes Arch Clin ExpOphthalmol. 2011;249(7):969-974. doi:10.1007/s00417-010-1581-9
52. Chan WM, Lai TY, Liu DT, Lam DS. Intravitreal bevacizumab(avastin) for choroidal neovascularization secondary to central serouschorioretinopathy, secondary to punctate inner choroidopathy, or ofidiopathic origin. Am J Ophthalmol. 2007;143(6):977-983. doi:10.1016/j.ajo.2007.02.039
53. Artunay O, Yuzbasioglu E, Rasier R, Sengul A, Bahcecioglu H.Intravitreal bevacizumab in treatment of idiopathic persistent centralserous chorioretinopathy: a prospective, controlled clinical study. CurrEye Res. 2010;35(2):91-98. doi:10.3109/02713680903428306
54. Lim JW, Ryu SJ, Shin MC. The effect of intravitreal bevacizumabin patients with acute central serous chorioretinopathy. Korean JOphthalmol. 2010;24(3):155-158. doi:10.3341/kjo.2010.24.3.155
55. Wang M, Munch IC, Hasler PW, Prünte C, Larsen M. Central serouschorioretinopathy. Acta Ophthalmol. 2008;86(2):126-145. doi:10.1111/j.1600-0420.2007.00889.x
56. Wilkinson-Berka JL, Tan G, Jaworski K, Harbig J, Miller AG.Identification of a retinal aldosterone system and the protective effects ofmineralocorticoid receptor antagonism on retinal vascular pathology.Circ Res. 2009;104(1):124-133. doi:10.1161/CIRCRESAHA.108.176008
57. Bousquet E, Beydoun T, Zhao M, Hassan L, Offret O, Behar-Cohen F. Mineralocorticoid receptor antagonism in the treatmentof chronic central serous chorioretinopathy: a pilot study. Retina.2013;33(10):2096-2102. doi:10.1097/IAE.0b013e318297a07a
58. Herold TR, Prause K, Wolf A, Mayer WJ, Ulbig MW. Spironolactonein the treatment of central serous chorioretinopathy - a case series.Graefes Arch Clin Exp Ophthalmol. 2014;252(12):1985-1991. doi:10.1007/s00417-014-2780-6
59. Gonzalez C. Décollements séreux rétiniens. Intérêt de l’acétazolamide[Serous retinal detachment. Value of acetazolamide]. J Fr Ophtalmol.1992;15(10):529-536.
60. Pikkel J, Beiran I, Ophir A, Miller B. Acetazolamide for central serousretinopathy. Ophthalmology. 2002;109(9):1723-1725. doi:10.1016/s0161-6420(02)01157-0
61. Avci R, Deutman AF. Die Behandlung der zentralen serösenChoroidopathie mit dem Betarezeptorenblocker Metoprolol (VorläufigeErgebnisse) [Treatment of central serous choroidopathy with thebeta receptor blocker metoprolol (preliminary results)]. Klin MonblAugenheilkd. 1993;202(3):199-205. doi:10.1055/s-2008-1045583
62. Tatham A, Macfarlane A. The use of propranolol to treat central serouschorioretinopathy: an evaluation by serial OCT. J Ocul Pharmacol Ther.2006;22(2):145-149. doi:10.1089/jop.2006.22.145
63. Fabianová J, Porubská M, Cepilová Z. Centrálna seróznachorioretinopatia--liecba betablokátormi [Central serouschorioretinopathy--treatment with beta blockers]. Cesk Slov Oftalmol.1998;54(6):401-404.
64. Chrapek O, Spacková K, Rehák J. Lécba centrální serózníchorioretinopatie betablokátory [Treatment of central serouschorioretinopathy with beta blockers]. Cesk Slov Oftalmol.2002;58(6):382-386.